Fairvalue-Calculator Fairvalue-Calculator
EN DE

Biomm S.A (BIOM3) Fair Value & Analysis

Healthcare · BR · Market cap R$936M

PriceR$6.20
Fair ValueR$0.8300
Upside-86.6%
Quality95/100
Evidence: Low Range R$0.8300 – R$1.17

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Biomm S.A (BIOM3) currently trades at R$6.20, while our model-based Fair Value estimate is R$0.8300 — implying the stock looks roughly 86.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and acute myocardial infarction; and RANIVISIO for treating vision problems related to abnormal blood vessel growth or fluid buildup in the retina. The company was incorporated in 2001 and is based in Nova Lima, Brazil.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Biomm S.A (BIOM3) undervalued?
As of Jun 24, 2026, our model estimates a fair value of R$0.8300 versus a price of R$6.20 — about −87% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BIOM3?
Our 21-model fair value for Biomm S.A is R$0.8300 (as of Jun 24, 2026), built from audited fundamentals. The current price is R$6.20.
What is the quality score of BIOM3?
Biomm S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.